DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22192/S-013

**SUPPLEMENT APPROVAL/**
**FULLFILLMENT OF POSTMARKETING REQUIREMENT**

Novartis Pharmaceuticals Corporation
Attention: Katiana Francois, MSJ
Global Program Regulatory Manager
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080

Dear Ms. Francois:

Please refer to your Supplemental New Drug Application (sNDA) dated and received on July 18, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Fanapt (iloperidone) 1, 2, 4, 6, 8, 10, and 12 mg tablets.

We acknowledge receipt of your amendments dated August 15, 2013, October 10, 2013, and January 23, 2014.

This "Prior Approval" supplemental new drug application provides for additional information on the use of Fanapt in patients with hepatic impairment with changes to Highlights, Section 2.2 Dosage in Special Population, and Section 8.7 Hepatic Impairment. The supplement also provides for changes to Section 7.2 Potential of Fanapt to Affect Other Drugs and Section 12.3 Pharmacokinetics, as well as minor editorial changes throughout the prescribing information. We note that these labeling changes were based upon a study report submitted on January 25, 2013.

## APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. Your agreement is noted in your email communication dated April 1, 2014.

## CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the

addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)**

We have received your submission dated January 25, 2013, containing the final report for the following postmarketing requirement listed in the May 6, 2009 approval letter.

4-5 A repeat of your clinical trial CIL0522A1013, conducted with a group of subjects with mildly and moderately impaired hepatic function, comparing them to normal in the same trial.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements and postmarketing commitments listed in the May 6, 2009 approval letter that are still open.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kimberly Updegraff, M.S., Regulatory Project Manager, at (301)796-2201.

Sincerely,

*{See appended electronic signature page}*

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

MITCHELL V Mathis
04/21/2014